

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>					
				<b>Application Number</b>	10/763,807				
				<b>Filing Date</b>	January 22, 2004				
				<b>First Named Inventor</b>	Shanler				
				<b>Group Art Unit</b>	1617				
				<b>Examiner Name</b>	Abigail Manda Cotton				
<b>Sheet</b>	1	of	2	<b>Attorney Docket Number</b>	132957.00101				
<b>U.S. PATENT DOCUMENTS</b>									
Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
		Number	Kind Code (if known)						
	A1	2007/0048234	A1	Waugh et al.	03-01-2007				
	A2	2005/0256204	A1	Bitter, Sr.	11-17-2005				
	A3	2005/0222101	A1	Huttrer	10-06-2005				
	A4	2004/0220259	A1	Yu et al.	11-04-2004				
	A5	2006/0264515		DeJovin et al.	11-23-2006				
	A6	2006/0171974		DeJovin et al.	08-03-2006				
	A7	2005/0276830		DeJovin et al.	12-15-2005				
	A8	2004/0242588		DeJovin et al.	12-02-2004				
	A9	4,853,216		Koslo et al.	08-01-1989				
	A10	2007/0082070	A1	Stokey et al.	04-12-2007				
<b>FOREIGN PATENT DOCUMENTS</b>									
Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T	
		Office	Number	Kind Code (if known)					
<b>OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>									
Examiner's Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or county where published.							T
	C1	CRAWFORD et al., Rosacea: I. Etiology, pathogenesis, and subtype classification, Sept. 2004, J. Am. Acad. Dermatol. 51(3):327-341							
	C2	PELLE et al., Rosacea: II. Therapy, Oct. 2004, Am. Acad. Dermatol. 51(4):499-512							
	C3	WILKIN et al., Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea, 2002, 46(4): 584-587							
	C4	PLEWIG et al., Acne and Rosacea, Acne and Rosacea, 2 <sup>nd</sup> Rev. Ed., Springer-Verlag Berlin, pp.433-475							
	C5	WILKIN, Why is flushing limited to a mostly facial cutaneous distribution?, Aug. 1988, J. Am. Acad. Dermatol. 2(1):309-313							
	C6	WILKIN, Oral Thermal-Induced Flushing in Erythematotelangiectatic Rosacea, 1981, J. Invest. Dermatol. 76:15-18							
	C7	PARODI et al., Flushing in Rosacea: An Experimental Approach, 1980, Archives of Dermatol. Res., Springer-Verlag, 269:269-273							
	C8	AHLQUIST, A Study of the Adrenotropic Receptors, June 1948, Adrenotropic Receptors 153:586-600							
	C9	KIRSTEIN et al., Autonomic Nervous System Pharmacogenomics: A Progress Report, 2004, Pharmacol. Rev. 56(1):31-52							
	C10	PIASCIK et al., $\alpha_1$ -Adrenergic Receptors: New Insights and Directions, 2001, J. Pharmacol. and Exper. Therap. 298(2):403-410							
	C11	CALZADA et al., Alpha-Adrenoceptor Subtypes, 2001, Pharmacol. Res. 44(3):195-207							
<b>Examiner Signature</b>					<b>Date Considered</b>				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KC/

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	10/763,807
				<b>Filing Date</b>	January 22, 2004
				<b>First Named Inventor</b>	Shanler
				<b>Group Art Unit</b>	1617
				<b>Examiner Name</b>	Abigail Manda Cotton
<b>Sheet</b>	2	<b>of</b>	2	<b>Attorney Docket Number</b>	132957.00101
	C12	GUIMARAES et al., Vascular Adrenoceptors: An Update, 2001, Am. Soc. Pharmacol. and Exper. Therapeutics, Pharmacol. Rev. 53(2):319-356			
	C13	HIEBLE, Subclassification and Nomenclature of $\alpha$ - and $\beta$ -Adrenoceptors, 2007, Curr. Topics in Medicinal Chem. 7:129-134			
	C14	JARAJAPU et al., Functional Characterization of $\alpha_1$ -Adrenoceptor Subtypes in Human Subcutaneous Resistance Arteries, 2001, J. Pharmacol. and Exp. Therapeutics 299(2):729-734			
	C15	LEECH et al., Different $\alpha$ -adrenoceptor subtypes mediate constriction of arterioles and venules, 1996, Am. Phys. Soc., pps. H710-H722			
	C16	CHALOTHORN et al., Differences in the Cellular Localization and Agonist-Mediated Internalization Properties of the $\alpha_1$ -Adrenoceptor Subtypes, 2002, Molec. Pharmacol. 61(5):1008-1016			
	C17	BISHOP, Recent Advances in the Discovery of $\alpha_1$ -Adrenoceptor Agonists, 2007, Curr. Topics Med. Chem. 7:135-145			
	C18	CRASSOUS et al., Interest of $\alpha_2$ -Adrenergic Agonists and Antagonists in Clinical Practice: Background, Facts and Perspectives, 2007, Curr. Topics med. Chem. 7:187-194			
	C19	GENTILI et al., Agonists and Antagonists Targeting the Different $\alpha_2$ -Adrenoceptor Subtypes, 2007, Curr. Topics Med. Chem. 7:163-186			
	C20	SPEAKE et al., 2-(Anilinomethyl)imidazolines as $\alpha_1$ Adrenergic Receptor Agonists: $\alpha_{1A}$ Subtype Selective 2' Heteroaryl Compounds, 2003, Bioorganic & Med. Chem. Letters 13:1183-1186			
	C21	PIGINI et al., Structure-Activity Relationship at $\alpha$ -Adrenergic Receptors Within a Series of Imidazoline Analogues of Cirazoline, 2000, Bioorganic & Med. Chem. 8:883-888			
	C22	CROSS et al., Transdermal and Penetration of Vasoconstrictors-Present Understanding and Assessment of the Human Epidermal Flux and Retention of Free Bases and Ion-Pairs, Feb. 2003, Pharma. Res. 20(2):270-274			
	C23	JENNI, Information Connection: Tips on Treating Acne, <a href="http://www.mindconnection.com/library/health/acnecare.htm">www.mindconnection.com/library/health/acnecare.htm</a>			
	C24	SCRUGGS et al., The teardrop sign: a rare dermatological reaction to brimonidine, 2004, Br. J. Ophthalmol 84:667			
	C25	RONA'S Skin Remedies, Beauty and Style, <a href="http://beauty.village.com/skinbody/facecare/0,,8h9s,00.html">beauty.village.com/skinbody/facecare/0,,8h9s,00.html</a>			
	C26	PETER LAMA'S Beauty Solutions, Tips for Beautiful Face and Body Skin, Beauty Magazine, <a href="http://www.lamasbeauty.com/beauty/solutions/tips_face_skin.htm">www.lamasbeauty.com/beauty/solutions/tips_face_skin.htm</a>			
	C27	HEALTH Boards, <a href="http://www.healthboards.com/boards/showthread.php?t=5725&amp;highlight=visine+zits">www.healthboards.com/boards/showthread.php?t=5725&amp;highlight=visine+zits</a>			
	C28	BRATSLAVSKY, DERMAdoctor, Skincare articles: your prescription for beautiful skin, <a href="http://www.dermadoctor.com/pages/newsletter221.asp">www.dermadoctor.com/pages/newsletter221.asp</a>			
	C29	ACNE.ORG, <a href="http://www.acne.org/messageboard/index.php?showtopic=34267">www.acne.org/messageboard/index.php?showtopic=34267</a>			
	C30	ACNETEAM.COM, <a href="http://www.acneteam.com/home-remedies-to-heal-acne-quick.html">www.acneteam.com/home-remedies-to-heal-acne-quick.html</a>			
	C31	Tetrahydrozoline hydrochloride, <a href="http://www.sigmaaldrich.com/catalog/search/ProductDetail/SIGMA/T4264">www.sigmaaldrich.com/catalog/search/ProductDetail/SIGMA/T4264</a>			
<b>Examiner Signature</b>	/Kendra Carter/			<b>Date Considered</b>	04/03/2008

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KC/